Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations from DECLARE-TIMI 58 Trial

Remo H.M. Furtado, Itamar Raz, Erica L. Goodrich, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Philip Aylward, Anthony J. Dalby, Mikael Dellborg, Doina Dimulescu, José C. Nicolau, Anthonius J.M. Oude Ophuis, Avivit Cahn, Ofri Mosenzon, Ingrid Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Stephen D. Wiviott

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Sort by
Weight
Alphabetically

Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations from DECLARE-TIMI 58 Trial

Fingerprint

Medicine & Life Sciences